COVID-19: Keep up to date with the latest pharmaceutical and healthcare news as the pandemic evolves

The Pharma Fast 50

PharmaTimes presents Alantra’s annual ranking of the fastest growing private pharma companies in the UK
Powerful progress

Veeva’s predictions for the life sciences industry in 2021
Cash controllers

Oli Hudson and Steve How, of Wilmington Healthcare, explore how NHS England’s new system-level funding works and the impact on prescribing for high cost drugs

News

View all

Cosentyx gains EU approval for new label extension

Label update includes data for axial manifestations of psoriatic arthritis

2nd March 2021

NHS prescription charges set to rise in England

Charge will increase to £9.35 per single prescription item from 1 April 2021

2nd March 2021

NICE backs selective internal radiation therapy for advanced liver cancer

Hundreds of people will be able to benefit from this treatment type

2nd March 2021

Cancer Research UK teams up with Teon on new cancer drug

Focus of the agreement is a first-in-class small molecule adenosine A2B receptor antagonist

2nd March 2021

Genomics plc scores $30m to expand patient-centric health platform

Latest funding round includes investments from Foresite Capital and F-Prime Capital

1st March 2021

Web Exclusives

View all

A new focus

Castleman disease (CD) is a rare and potentially life-threatening disease. Like so many rare diseases, it is often misdiagnosed, or goes undiagnosed. On Rare Disease Day, EUSA Pharma’s Jon Morgan, VP global head of Medical, discusses the need to bring a new focus to rare diseases like CD

A call to action

If we want to beat COVID-19, vaccination must be an urgent global effort

Tackling two crises at once

A look at the benefits of using cardboard packaging in the transport of vaccines

A collaborative approach

Success is usually not a linear process – home treatments for COVID-19, in tandem with an effective vaccine, could place a large dent into this pandemic

Magazine

View more from the latest edition

Time for change

Why governments need to rethink their regulatory framework in 2021

Smart People: Andrew Meade

PharmaTimes talks to Andrew Meade, Accenture’s UK and Ireland Life Sciences lead, about the opportunities and challenges triggered by COVID-19 for medicine and digital tech

In sickness and in health

Exploring the relationship between the microbiome, precision medicine and cancer

The missing piece of the puzzle

Supplementing disease modelling with microbiome data is set to enable the life sciences industry to understand more about how drugs interact with different people, and devise more targeted treatments. Anthony Finbow explains how the science of microbiomes will increasingly contribute to pharma research outcomes

Hidden impact

The effect of the COVID-19 pandemic on lung cancer care, and learning lessons from across Europe

A global effort?

COVID-19 threw pharma’s performance on access to medicine into the spotlight. Has the industry passed the test?

Cash controllers

Oli Hudson and Steve How, of Wilmington Healthcare, explore how NHS England’s new system-level funding works and the impact on prescribing for high cost drugs